# Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients

> **NCT05732051** · PHASE2 · RECRUITING · sponsor: **University Hospital, Akershus** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- Cancer Therapy-Related Cardiac Dysfunction
- Cardiotoxicity
- Heart Failure

## Interventions

- **DIETARY_SUPPLEMENT:** Nicotinamide Riboside
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT05732051
- **Lead sponsor:** University Hospital, Akershus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-16
- **Primary completion:** 2025-08-01
- **Final completion:** 2035-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-03-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732051, "Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05732051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*